Potential molecular targets for regulating metabolism and apoptosis of A375 human melanoma cells under conditions of altered redox status
https://doi.org/10.18699/SSMJ20260302
Abstract
The aim of the study is to describe potential molecular targets for regulating metabolism and apoptosis of A375 tumor cells under conditions of altered redox status. The relevance of the study is justified by the aggressive nature of melanoma, its high metastatic potential, and the resistance of tumor cells to reactive oxygen species. The use of the human melanoma cell line A375, which carries the BRAFV600E mutation, serves as a valuable model for investigating mechanisms of drug resistance in tumor cells. Under conditions of altered redox status, oxidative modifications of proteins occur, which in turn affect the functional activity of proteins that regulate metabolism. The systems of glutathione, glutaredoxin, and thioredoxin play a key role in regulating the oxidative modification of macromolecules. The conformational arrangement of protein molecules in response to changes in redox status directly influences the proliferative activity, functionality, and survival of tumor cells. By discovering the molecular mechanisms that regulate metabolism in tumor cells during changes in redox status, we could identify potential molecular targets for activating apoptosis. The information presented in this review logically supports the use of changes in redox status and oxidative modification of proteins as molecular mechanisms for regulating cellular metabolism and apoptosis in A375 melanoma cells.
About the Authors
O. L. Nosareva
Siberian State Medical University of Minzdrav of Russia
Russian Federation
Russian Federation
Ol’ga L. Nosareva, doctor of medical sciences
634050, Tomsk, Moscovsky path, 2
E. A. Stepovaya
Siberian State Medical University of Minzdrav of Russia
Russian Federation
Russian Federation
Elena A. Stepovaya, doctor of medical sciences, professor
634050, Tomsk, Moscovsky path, 2
K. A. Kuanysheva
Siberian State Medical University of Minzdrav of Russia
Russian Federation
Russian Federation
Kristina A. Kuanysheva
634050, Tomsk, Moscovsky path, 2
K. P. Vorobev
Siberian State Medical University of Minzdrav of Russia
Russian Federation
Russian Federation
Kirill P. Vorobev
634050, Tomsk, Moscovsky path, 2
L. V. Spirina
Siberian State Medical University of Minzdrav of Russia
Russian Federation
Russian Federation
Ludmila V. Spirina, doctor of medical sciences
634050, Tomsk, Moscovsky path, 2
V. M. Nagaitsev
Altai Regional Oncology Dispensary
Russian Federation
Russian Federation
Vladimir M. Nagaitsev, candidate of medical sciences
656045, Barnaul, Zmeinogorsky path, 110
References
1. Vandyck H.H., Hillen L.M., Bosisio F.M., van den Oord J., Zur Hausen A., Winnepenninckx V. Rethinking the biology of metastatic melanoma: a holistic approach. Cancer Metastasis Rev. 2021;40(2):603–624. doi: 10.1007/s10555-021-09960-8
2. Sagwal S.K., Bekeschus S. ROS Pleiotropy in melanoma and local therapy with physical modalities. Oxid. Med. Cell. Longev. 2021;2021:6816214. doi: 10.1155/2021/6816214
3. Carvalho L.A.C., Queijo R.G., Baccaro A.L.B., Siena Á.D.D., Silva W.A. Jr., Rodrigues T., Maria-Engler S.S. Redox-related proteins in melanoma progression. Antioxidants (Basel). 2022;11(3):438. doi: 10.3390/antiox11030438
4. Venza I., Venza M., Visalli M., Lentini G., Teti D., d’Alcontres F.S. ROS as regulators of cellular processes in melanoma. Oxid. Med. Cell. Longev. 2021;2021:1208690. doi: 10.1155/2021/1208690
5. Linos E., Swetter S.M., Cockburn M.G., Colditz G.A., Clarke C.A. Increasing burden of melanoma in the United States. J. Invest. Dermatol. 2009;129(7):1666–1674. doi: 10.1038/jid.2008.423
6. Dorard C., Estrada C., Barbotin C., Larcher M., Garancher A., Leloup J., Beermann F., Baccarini M., Pouponnot C., Larue L., Eychène A., Druillennec S. RAF proteins exert both specific and compensatory functions during tumour progression of NRAS-driven melanoma. Nat. Commun. 2017;8:15262. doi: 10.1038/ncomms15262
7. Yargunin S.A., Lasarev A.F. Skin melanoma. State of the problem. Review. Rossiyskiy onkologicheskiy zhurnal =Russian Journal of Oncology. 2019;24:(3-6):113–120. [In Russian]. doi: 10.18821/1028-9984-2019-24-3-6-113-120
8. Arslanbaeva L.R., Santoro M.M. Adaptive redox homeostasis in cutaneous melanoma. Redox Biol. 2020;37:101753. doi: 10.1016/j.redox.2020.101753
9. Zhen Li., Fang Y., Chen H., Zhang T., Yin X., Man J., Yang X., Lu M. Spatiotemporal trends of the global burden of melanoma in 204 countries and territories from 1990 to 2019: Results from the 2019 global burden of disease study. Neoplasia. 2022;24(1):12–21. doi: 10.1016/j.neo.2021.11.013
10. Skin Cancer Rates by Country / Melanoma Rates by Country 2026. Available at: https://worldpopulationreview.com/country-rankings/skin-cancer-ratesby-country
11. Kiuru M., Busam K.J. The NF1 gene in tumor syndromes and melanoma. Lab. Invest. 2017;97(2):146–157. doi: 10.1038/labinvest.2016.142
12. Sale M.J., Balmanno K., Cook S.J. Resistance to ERK1/2 pathway inhibitors; sweet spots, fitness deficits and drug addiction. Cancer Drug. Resistance. 2019;2(2):365–380. doi: 10.20517/cdr.2019.14
13. Vasudevan S., Flashner-Abramson E., Alkhatib H., Chowdhury S.R., Adejumobi I.A., Vilenski D., Stefansky S., Rubinstein A.M., Kravchenko-Balasha N. Overcoming resistance to BRAFV600E inhibition in melanoma by deciphering and targeting personalized protein network alterations. NPJ Precis. Oncol. 2021;5(1):50. doi: 10.1038/s41698-021-00190-3
14. Feichtenschlager V., Zheng Y.J., Ho W., Chen L., Callanan C., Chen C., Lee A., Ortiz J., Rappersberger K., Ortiz-Urda S. Deconstructing the role of MALAT1 in MAPK-signaling in melanoma: insights from antisense oligonucleotide treatment. Oncotarget. 2023;14:543–560. doi: 10.18632/oncotarget.28447
15. Madej E., Brożyna A.A., Adamczyk A., Wronski N., Harazin-Lechowska A., Muzyk A., Makuch K., Markiewicz M., Rys J., Wolnicka-Glubisz A. Vemurafenib and dabrafenib downregulates RIPK4 level. Cancers (Basel). 2023;15(3):918. doi: 10.3390/cancers15030918
16. Posch C., Vujic I., Monshi B., Sanlorenzo M., Weihsengruber F., Rappersberger K., Ortiz-Urda S. Searching for the chokehold of NRAS mutant melanoma. J. Invest. Dermatol. 2016;136(7):1330–1336. doi: 10.1016/j.jid.2016.03.006
17. Kazubskaya T.P., Mekheda L.V., Trofimov E.I., Fomina L.Ya., Kharkevich G.Yu., Belysheva T.S., Kozlova V.M., Sorokina S.S., Fridman M.V. Melanoma, molecular and genetic aspects of etiopathogenesis: classification, epidemiology, risk factors, braf and nras mutations. Voprosy onkologii = Problems in Oncology. 2022;68(6):725–732. [In Russian]. doi: 10.37469/0507-3758-2022-68-6-725-732
18. Tímár J., Ladányi A. Molecular pathology of skin melanoma: Epidemiology, differential diagnostics, prognosis and therapy prediction. Int. J. Mol. Sci. 2022;23(10):5384. doi: 10.3390/ijms23105384
19. Mizuno S., Ikegami M., Koyama T., Sunami K., Ogata D., Kage H., Yanagaki M., Ikeuchi H., Ueno T., Tanikawa M., Oda K., Osuga Y., Mano H., Kohsaka S. High-throughput functional evaluation of MAP2K1 variants in cancer. Mol. Cancer Ther. 2023;22(2):227–239. doi: 10.1158/1535-7163.MCT-22-0302
20. Wang H., Tran T.T., Duong K.T., Nguyen T., Le U.M. Options of therapeutics and novel delivery systems of drugs for the treatment of melanoma. Mol. Pharm. 2022;19(12):4487–4505. doi: 10.1021/acs.molpharmaceut.2c00775
21. Ko B., Takebe N., Andrews O., Makena M.R., Chen A.P. rethinking oncologic treatment strategies with interleukin-2. Cells. 2023;12(9):1316. doi: 10.3390/cells12091316
22. Wu C.F., Wang H.M., Huang W.K., Chang J.W. Efficacy and safety of bio-chemotherapy with dacarbazine plus interleukin-2 in patients with unresectable malignant melanoma. Asia Pac. J. Clin. Oncol. 2015;11(4):314–318. doi: 10.1111/ajco.12404
23. Men’shchikova E.B., Zenkov N.K., Lankin V.Z., Bondar’ I.A., Trufakin V.A. Oxidative stress. Pathological states and diseases. Novosibirsk: ARTA, 2008. 284 р. [In Russian].
24. Gutteridge J.M.C., Halliwell B. Mini-review: Oxidative stress, redox stress or redox success? Biochem. Biophys. Res. Commun. 2018;502(2):183–186. doi: 10.1016/j.bbrc.2018.05.045
25. Dominko K., Đikić D. Glutathionylation: a regulatory role of glutathione in physiological processes. Arh. Hig. Rada Toksikol. 2018;69(1):1–24. doi: 10.2478/aiht-2018-69-2966
26. Niu B., Liao K., Zhou Y., Wen T., Quan G., Pan X., Wu C. Application of glutathione depletion in cancer therapy: Enhanced ROS-based therapy, ferroptosis, and chemotherapy. Biomaterials. 2021;277:121110. doi: 10.1016/j.biomaterials.2021.121110
27. Wang H., Yang L., Liu M., Luo J. Protein post-translational modifications in the regulation of cancer hallmarks. Cancer Gene Ther. 2023;30(4):529–547. doi: 10.1038/s41417-022-00464-3
28. Zaslona Z., O’Neill L.A.J. Cytokine-like roles for metabolites in immunity. Mol. Cell. 2020;78(5):814–823. doi: 10.1016/j.molcel.2020.04.002
29. Kalinina E.V., Gavriliuk L.A. Glutathione synthesis in cancer cells. Biochemistry (Mosc). 2020;85(8):895–907. doi: 10.1134/S0006297920080052
30. Corso C.R., Acco A. Glutathione system in animal model of solid tumors: From regulation to therapeutic target. Crit. Rev. Oncol. Hematol. 2018;128:43–57. doi: 10.1016/j.critrevonc.2018.05.014
31. Murphy M.P., Hartley R.C. Mitochondria as a therapeutic target for common pathologies. Nat. Rev. Drug. Discov. 2018;17:865–886. doi: 10.1038/nrd.2018.174
32. Candido S., Salemi R., Piccinin S., Falzone L., Libra M. The PIK3CA H1047R mutation confers resistance to BRAF and MEK inhibitors in A375 melanoma cells through the cross-activation of MAPK and PI3KAkt pathways. Pharmaceutics. 2022;14(3):590. doi: 10.3390/pharmaceutics14030590
33. de Backer J., Hoogewijs D. The cytoglobin-dependent transcriptome in melanoma indicates a protective function associated with oxidative stress, inflammation and cancer-associated pathways. Sci. Rep. 2024;14(1):18175. doi: 10.1038/s41598-024-69224-7
34. Attri P., Park J.H., de Backer J., Kim M., Yun J.H., Heo Y., Dewilde S., Shiratani M., Choi E.H., Lee W., Bogaerts A. Structural modification of NADPH oxidase activator (Noxa 1) by oxidative stress: An experimental and computational study. Int. J. Biol. Macromol. 2020;163:2405–2414. doi: 10.1016/j.ijbiomac.2020.09.120
35. Li X., Zhou L., Zhang Y., He X., Lu H., Zhang L., Tian Y., Liu X., Zheng H., Shao J., Long M. mGPDH Deficiency leads to melanoma metastasis via induced NRF2. J. Cell. Mol. Med. 2021;25(11):5305–5315. doi: 10.1111/jcmm.16542
36. Sarowar S., Cirillo D., Játiva P., Nilsen M.H., Otragane S.A., Heggdal J., Selheim F., Ceña V., Bjørsvik H.R., Enger P.Ø. The styryl benzoic acid derivative DC10 potentiates radiotherapy by targeting the xCT-glutathione axis. Front. Oncol. 2022;12:786739. doi: 10.3389/fonc.2022.786739
37. Tyurina Y.Y., Kapralov A.A.., Tyurin V.A., Shurin G., Amoscato A.A., Rajasundaram D., Tian H., Bunimovich Y.L., Nefedova Y., Herrick W.G., Parchment R.E., Doroshow J.H., Bayir H., Srivastava A.K., Kagan V.E. Redox phospholipidomics discovers pro-ferroptotic death signals in A375 melanoma cells in vitro and in vivo. Redox Biol. 2023;61:102650. doi: 10.1016/j.redox.2023.102650
38. Jandova J., Wondrak G.T. Genomic GLO1 deletion modulates TXNIP expression, glucose metabolism, and redox homeostasis while accelerating human A375 malignant melanoma tumor growth. Redox Biol. 2021;39:101838. doi: 10.1016/j.redox.2020.101838
39. Cirillo D., Sarowar S., Øyvind Enger P., Bjørsvik H.R. Structure-activity-relationship-aided design and synthesis of xCT antiporter inhibitors. ChemMed-Chem. 2021;16(17):2650–2668. doi: 10.1002/cmdc.202100204
40. Nosareva O.L., Stepovaya E.A. Role of oxidative modification of proteins in the regulation and realization of cell death of blood lymphocytes under the conditions of blocking glutathione synthesis under oxidative stress. Meditsinskaya immunologiya = Medical Immunology. 2024;26(4):671–676. [In Russian]. doi: 10.15789/1563-0625-ROO-16615
41. Nosareva O.L., Stepovaya E.A., Shakhristova E.V., Alekseeva O.N., Kuzmenko D.I., Sadykova A.A., Novitsky V.V. The role of redox status and oxidative modification of proteins in implementing apoptosis in human blood lymphocytes in norm and under experimental oxidative stress. Rossiyskiy fiziologicheskiy zhurnal imeni Ivana Mikhaylovicha Sechenova = Russian Journal of Physiology. 2019;105(3):327–338. [In Russian]. doi: 10.1134/S0869813919030063
42. Terzuoli E., Bellan C., Aversa S., Ciccone V., Morbidelli L., Giachetti A., Donnini S., Ziche M. ALDH3A1 Overexpression in melanoma and lung tumors drives cancer stem cell expansion, impairing immune surveillance through enhanced PD-L1 output. Cancers. 2019;11(12):1963. doi: 10.3390/cancers11121963
43. Melo F.H.Md., Gonçalves D.A., Sousa R.Xd., Icimoto M.Y., Fernandes Dd.C., Laurindo F.R.M., Jasiulionis M.G. Metastatic melanoma progression is associated with endothelial nitric oxide synthase uncoupling induced by loss of eNOS:BH4 stoichiometry. Int. J. Mol. Sci. 2021;22(17):9556. doi: 10.3390/ijms22179556
44. Hawkins C.L., Davies M.J. Detection, identification, and quantification of oxidative protein modifications. J. Biol. Chem. 2019;294(51):19683–19708. doi: 10.1074/jbc.REV119.006217
45. Dilek O. Current probes for imaging carbonylation in cellular systems and their relevance to progression of diseases. Technol. Cancer Res. Treat. 2022;21:15330338221137303. doi: 10.1177/15330338221137303
46. Nosareva O.L., Ryazantseva N.V., Stepovaya E.A., Shakhristova E.V., Stepanova E.A., Gulaya V.S. The role of heat shock proteins 27 and 70 in redox-dependent regulation of apoptosis in Jurkat tumor cells. Biomeditsinskaya khimiya = Biomedical Chemistry. 2016;62(6):670–673. [In Russian]. doi: 10.18097/PBMC20166206670
47. Nosareva O.L., Stepovaya E.A., Litvinova L.S., Yurova K.A. Heat shock protein Hsp27 and the status of the glutathione system in dexamethasone-induced apoptosis of Jurkat tumor cells. Bull. Exp. Biol. Med. 2024;176(5):617–619. doi: 10.1007/s10517-024-06079-y
48. Dubinina E.E. Products of oxygen metabolism in the functional activity of cells (life and death, creation and destruction). Physiological, clinical and biochemical aspects. Saint-Petersburg: Meditsinskaya Pressa, 2006. 400 p. [In Russian].
49. Ogata F.T., Branco V., Vale F.F., Coppo L. Glutaredoxin: Discovery, redox defense and much more. Redox Biol. 2021;43:101975. doi: 10.1016/j.redox.2021.101975
50. Lennicke C., Rahn J., Lichtenfels R., Wessjohann L.A., Seliger B. Hydrogen peroxide – production, fate and role in redox signaling of tumor cells. Cell. Commun. Signal. 2015;13:39. doi: 10.1186/s12964-015-0118-6
51. Kennedy L., Sandhu J.K., Harper M.E., Cuperlovic-Culf M. Role of glutathione in cancer: From mechanisms to therapies. Biomolecules. 2020;10(10):1429. doi: 10.3390/biom10101429
52. Kalinina E., Novichkova M. Glutathione in protein redox modulation through S-glutathionylation and S-nitrosylation. Molecules. 2021;26(2):435. doi: 10.3390/molecules26020435
53. Vašková J., Kočan L., Vaško L., Perjési P. Glutathione-related enzymes and proteins: A review. Molecules. 2023;28(3):1447. doi: 10.3390/molecules28031447
54. Kalinina E.V., Chernov N.N., Novichkova M.D. Role of glutathione, glutathione transferase, and glutaredoxin in regulation of redox-dependent processes. Biochemistry (Mosc.). 2014;79(13):1562–1583. doi: 10.1134/S0006297914130082
55. Chai Y.C., Mieyal J.J. Glutathione and glutaredoxin-key players in cellular redox homeostasis and signaling. Antioxidants (Basel). 2023;12(8):1553. doi: 10.3390/antiox12081553
56. Miller C.G., Holmgren A., Arnér E.S.J., Schmidt E.E. NADPH-dependent and -independent disulfide reductase systems. Free Radic. Biol. Med. 2018;127:248–261. doi: 10.1016/j.freeradbiomed.2018.03.051
57. Scirè A., Cianfruglia L., Minnelli C., Bartolini D., Torquato P., Principato G., Galli F., Armeni T. Glutathione compartmentalization and its role in glutathionylation and other regulatory processes of cellular pathways. Biofactors. 2019;45(2):152–168. doi: 10.1002/biof.1476
58. Kalinina E.V., Chernov N.N., Saprin A.N. Involvement of thio-, peroxi-, and glutaredoxins in cellular redox-dependent processes. Biochemistry (Mosc). 2008;73(13):1493–1510. doi: 10.1134/s0006297908130099
59. Jastrząb A., Skrzydlewska E. Thioredoxin-dependent system. Application of inhibitors. J. Enzyme Inhib. Med. Chem. 2021;36(1):362–371. doi: 10.1080/14756366.2020.1867121
60. Dobrovolska O., Rychkov G., Shumilina E., Nerinovski K., Schmidt A., Shabalin K., Yakimov A., Dikiy A. Structural insights into interaction between mammalian methionine sulfoxide reductase B1 and thioredoxin. J. Biomed. Biotechnol. 2012;2012:586539. doi: 10.1155/2012/586539
61. Mohammadi F., Soltani A., Ghahremanloo A., Javid H., Hashemy S.I. The thioredoxin system and cancer therapy: a review. Cancer Chemother. Pharmacol. 2019;84(5):925–935. doi: 10.1007/s00280-019-03912-4
62. Goldberg S.F., Miele M.E., Hatta N., Takata M., Paquette-Straub C., Freedman L.P., Welch D.R. Melanoma metastasis suppression by chromosome 6: evidence for a pathway regulated by CRSP3 and TXNIP. Cancer Res. 2003;63(2):432–440.
63. Fujii J., Ochi H., Yamada S. A comprehensive review of peroxiredoxin 4, a redox protein evolved in oxidative protein folding coupled with hydrogen peroxide detoxification. Free Radic. Biol. Med. 2025;227:336–354. doi: 10.1016/j.freeradbiomed.2024.12.015
64. Rhee S.G. Overview on peroxiredoxin. Mol. Cells. 2016;39(1):1–5. doi: 10.14348/molcells.2016.2368
65. Carvalho L.A.C., Truzzi D.R, Fallani T.S., Alves S.V., Toledo J.C.Jr., Augusto O., Netto L.E.S., Meotti F.C. Urate hydroperoxide oxidizes human peroxiredoxin 1 and peroxiredoxin 2. J. Biol. Chem. 2017;292(21):8705–8715. doi: 10.1074/jbc.M116.767657
66. Peskin A.V., Pace P.E., Behring J.B., Paton L.N., Soethoudt M., Bachschmid M.M., Winterbourn C.C. Glutathionylation of the active site cysteines of peroxiredoxin 2 and recycling by glutaredoxin. J. Biol. Chem. 2016;291(6):3053–3062. doi: 10.1074/jbc.M115.692798
Review
Views:
227
JATS XML
Email this article 